Raymond James Financial, Inc. reiterated their strong-buy rating on shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) in a research note issued to investors on Thursday. They currently have a $36.00 price target on the specialty pharmaceutical company’s stock.

PRTK has been the subject of a number of other research reports. HC Wainwright boosted their target price on shares of Paratek Pharmaceuticals from $36.00 to $43.00 and gave the company a buy rating in a research report on Tuesday, July 18th. Cantor Fitzgerald set a $50.00 price target on Paratek Pharmaceuticals and gave the company a buy rating in a research note on Monday, July 17th. BidaskClub downgraded Paratek Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Monday, July 24th. Finally, Zacks Investment Research raised Paratek Pharmaceuticals from a hold rating to a buy rating and set a $21.00 price target for the company in a research note on Saturday, August 5th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $37.44.

Shares of Paratek Pharmaceuticals (PRTK) opened at 24.55 on Thursday. Paratek Pharmaceuticals has a 12 month low of $9.80 and a 12 month high of $26.10. The stock has a 50 day moving average of $21.57 and a 200-day moving average of $20.40. The company’s market cap is $681.53 million.

Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.89) by $0.25. The business had revenue of $7.51 million during the quarter, compared to the consensus estimate of $7.50 million.

WARNING: This report was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://theolympiareport.com/2017/08/28/paratek-pharmaceuticals-inc-prtk-stock-rating-reaffirmed-by-raymond-james-financial-inc.html.

In related news, CFO Douglas W. Pagan sold 4,595 shares of the business’s stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $25.00, for a total value of $114,875.00. Following the completion of the transaction, the chief financial officer now owns 51,000 shares of the company’s stock, valued at $1,275,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Adam Woodrow sold 3,800 shares of the business’s stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $23.58, for a total value of $89,604.00. Following the transaction, the vice president now directly owns 69,500 shares of the company’s stock, valued at approximately $1,638,810. The disclosure for this sale can be found here. In the last ninety days, insiders sold 21,960 shares of company stock valued at $524,342. 4.90% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Broadfin Capital LLC increased its position in shares of Paratek Pharmaceuticals by 23.7% in the second quarter. Broadfin Capital LLC now owns 277,020 shares of the specialty pharmaceutical company’s stock valued at $6,676,000 after buying an additional 53,158 shares during the last quarter. California State Teachers Retirement System increased its position in shares of Paratek Pharmaceuticals by 7.2% in the second quarter. California State Teachers Retirement System now owns 41,722 shares of the specialty pharmaceutical company’s stock valued at $1,006,000 after buying an additional 2,800 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Paratek Pharmaceuticals by 21.0% in the second quarter. The Manufacturers Life Insurance Company now owns 18,650 shares of the specialty pharmaceutical company’s stock valued at $449,000 after buying an additional 3,233 shares during the last quarter. State Street Corp increased its position in shares of Paratek Pharmaceuticals by 112.3% in the second quarter. State Street Corp now owns 616,112 shares of the specialty pharmaceutical company’s stock valued at $14,850,000 after buying an additional 325,856 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Paratek Pharmaceuticals by 40.9% in the second quarter. Goldman Sachs Group Inc. now owns 131,723 shares of the specialty pharmaceutical company’s stock valued at $3,175,000 after buying an additional 38,222 shares during the last quarter. 82.33% of the stock is owned by hedge funds and other institutional investors.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.